LMAT

Rating neutralAI Memo

LeMaitre Vascular

As of 2026-08-06/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Quarterly dividend payment • 2026-09-03

Base target: $88 / p=50% prob

Biggest risk

The full-year guide reduction, Q2 catheter decline tied to recall-driven overstocking, narrower product and customer concentration, and execution demands from international expansion could keep the stock below prior valuation levels.

Invalidation

Break below $65 or thesis failure.

What would change my mind?

Strong Q2 organic growth, Artegraft momentum, higher pricing, mix, operating efficiencies, and substantial cash support a recovery toward the reported $116.25 median target if the guidance reset proves conservative.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-06

Base target

$88

p=50%

Bull target

$105

p=30%

Bear target

$65

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Mixed Q2 print resets the near-term valuation debate
Artegraft international expansion remains the core growth driver
Strong Q2 organic growth, Artegraft momentum, higher pricing, mix, operating efficiencies, and substantial cash support a recovery toward the reported $116.25 median target if the guidance reset proves conservative.

BearKey bullets

Catheter sales fell 11% in Q2 due to recall-driven overstocking in the year-ago period.
Full-year 2026 sales, operating-income, and EPS guidance declined from the prior May outlook.
International launch execution, sales-force expansion, and six warehouse expansions may increase operating complexity.

WatchKey bullets

Quarterly dividend payment

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $88 (p=50%)

Target spread vs base: +19% / -26%

Scenario probabilities

Bull Target: $105 (p=30%)Base Target: $88 (p=50%)Bear Target: $65 (p=20%)

Commentary

Primary evidence is strong and Q2 operating trends were positive, but the lower full-year outlook makes the earnings read-through mixed. The packet does not provide consensus comparisons, analyst revisions, options data, social coverage, or a trusted explanation of the post-print price move; the $79 August 5 anchor therefore supports monitoring rather than high-conviction re-rating.

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Mixed Q2 print resets the near-term valuation debate
Artegraft international expansion remains the core growth driver

Scenarios

Bull Target (Scenario probability)

$105 / p=30% prob

Base Target (Scenario probability)

$88 / p=50% prob

Bear Target (Scenario probability)

$65 / p=20% prob

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.45

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-03
Quarterly dividend payment
The board approved a $0.25 per-share quarterly dividend, payable September 3, 2026, to shareholders of record August 20, 2026. This is a modest shareholder-return support rather than a major operating catalyst. [#SEC-8K-2026-08-04]
Prob 98.00% • Move 1.00% • Priced-in 95.00%

Short-term Catalysts

Next few weeks

Mixed Q2 print resets the near-term valuation debate
2026-08-06
Q2 sales rose 10%, EPS rose 23%, gross margin expanded to 72.1%, and cash reached $376.2 million. However, reported sales and EPS were below the prior Q2 guidance midpoints, while full-year sales, operating-income, and EPS guidance were reduced versus the May outlook. Consensus surprise and post-print analyst revisions are unavailable. [#SEC-8K-2026-08-04] [#SEC-8K-2026-05-05]
Prob 75% • Move 5% • Priced-in 65%

Long-term Catalysts

Months to a year

Artegraft international expansion remains the core growth driver
2026-12-31
Management reported Artegraft sales growth of 34% in Q2, with the product approved in 56 countries and representing 21% of sales. Continued direct-market expansion, sales-force investment, and six international warehouse expansions could support sustained growth, but execution and the lower full-year guide limit conviction. [#SEC-8K-2026-08-04]
Prob 65% • Move 18% • Priced-in 55%

Risks

Catheter sales fell 11% in Q2 due to recall-driven overstocking in the year-ago period.
Full-year 2026 sales, operating-income, and EPS guidance declined from the prior May outlook.
International launch execution, sales-force expansion, and six warehouse expansions may increase operating complexity.
Recent open-market insider sales by the CEO and other insiders are a negative monitoring signal, but do not establish an operating weakness. [#SEC-FORM4-2026-05-11]
The business remains relatively concentrated in vascular devices and the vascular-surgeon customer base.

Peers

Symbol	Summary
BSX	Broader cardiovascular-medtech peer; LMAT’s smaller, narrower vascular-surgery exposure requires continued clean execution to sustain a premium growth profile.
EW	Large cardiovascular-device peer and useful scale reference; LMAT offers a more focused growth story but has less diversification.
ENOV	Closer in market capitalization but only a loose device comp; useful mainly for highlighting that LMAT’s valuation depends on sustained execution rather than size alone.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

Loading AI feed…

Symbol

Summary

BSX

Broader cardiovascular-medtech peer; LMAT’s smaller, narrower vascular-surgery exposure requires continued clean execution to sustain a premium growth profile.

Large cardiovascular-device peer and useful scale reference; LMAT offers a more focused growth story but has less diversification.

ENOV

Closer in market capitalization but only a loose device comp; useful mainly for highlighting that LMAT’s valuation depends on sustained execution rather than size alone.